Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Viazis Nikos, Toruner Murat, Papastergiou Vasilios, Mousourakis Konstantinos, Christidou Angeliki, Tzouvala Maria, Zacharopoulou Eirini, Palatianou Maria, Theocharis Georgios, Geramoutsos Georgios, Theodoropoulou Angeliki, Karmiris Konstantinos, Velegraki Magdalini, Ferhat Çelik Aykut, Akpinar Atilla, Zampeli Evanthia, Papathanasiou Evgenia, Unal Nalan Gulsen, Kapsoritakis Andreas, Argyriou Konstantinos, Christodoulou Dimitrios, Katsanos Konstantinos, Fousekis Fotios, Karakan Tarkan, Koutroubakis Ioannis E, Drygiannakis Ioannis, Giouleme Olga, Kalogirou Maria, Vlachou Evangelina, Liatsos Christos, Kyriakos Nikolaos, Tsironi Eftychia, Markopoulos Panagiotis, Bamias George, Chalakatevaki Konstantina, Tsiolakidou Georgia, Lamouri Charikleia, Tribonias George, Dimopoulou Konstantina, Kasapidis Panagiotis, Paraskeva Konstantina, Telli Pelin, Akyuz Filiz
Аннотация
METHODS: This multicenter retrospective cohort study collected data from consecutive IBD patients followed at referral centers in Greece and Turkey, who had received intensified anti-TNF regimens due to secondary loss of response. Clinical response, steroid-free clinical remission, biochemical response, or mucosal healing were evaluated at 3 and 6 months following dose escalation. Multivariate analysis was used to identify predictors of successful dose deescalation.
RESULTS: A total of 1129 patients were included [Crohn's disease: n = 743; ulcerative colitis: n = 386; infliximab (IFX): n = 650; adalimumab (ADA): n = 471; and golimumab (GOL): n = 8]. The median interquartile range (IQR) duration of anti-TNF treatment before escalation was 13.0 (6.0-36.0) months. After a median (IQR) of 16.0 (8.0-36.0) months of intensified therapy, 283 (25.1%) patients were successfully deescalated to standard anti-TNF dosing, 340 (30.1%) remained on the intensified regimen, and 506 (44.8%) were switched to a different agent - either another anti-TNF ( n = 111, 21.9%) or a biologic with a different mechanism of action ( n = 395, 78.1%). Predictors of successful deescalation included the concomitant use of steroids and the type of anti-TNFa agent used (IFX vs. ADA/GOL). Negative predictors included the presence of extraintestinal manifestations, prior anti-TNF exposure (i.e. ADA followed by IFX and vice versa), and longer duration of anti-TNF therapy before escalation.
CONCLUSION: One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months.